COVID-19疫苗与特殊关注不良事件:跨国全球疫苗数据网络(GVDN)9900万接种者队列研究
该跨国观察性队列研究覆盖8国10个站点、9906万8901名接种者,比较13种选定特殊关注不良事件(AESI)的观察发生率与接种前预期发生率。接种ChAdOx1首剂后吉兰-巴雷综合征和脑静脉窦血栓形成、接种mRNA-1273首剂后急性播散性脑脊髓炎、以及三种疫苗后心肌炎和心包炎的观察/预期比值(OE比)95%CI下限均大于1.5。结论确认了心肌炎、心包炎、吉兰-巴雷综合征和脑静脉窦血栓形成的既定安全信号,并识别出需进一步调查的其他潜在信号。
要点
- ChAdOx1首剂后吉兰-巴雷综合征OE比2.49(95%CI 2.15-2.87),脑静脉窦血栓形成OE比3.23(95%CI 2.51-4.09)。
- mRNA-1273首剂后急性播散性脑脊髓炎OE比3.78(95%CI 1.52-7.78)。
- BNT162b2、mRNA-1273和ChAdOx1接种后心肌炎和心包炎OE比显著升高,95%CI下限均大于1.5。
核心结论
- 该多国分析确认了心肌炎、心包炎、吉兰-巴雷综合征和脑静脉窦血栓形成的既定安全信号。
- 识别出其他需进一步调查的潜在安全信号。
研究设计与样本
- 观察性队列研究,采用共同方案比较13种选定AESI的观察发生率与预期发生率。
- 共纳入9906万8901名接种者,覆盖8个国家10个站点。
- 研究期间接种BNT162b2 1亿8355万9462剂、mRNA-1273 3617万8442剂、ChAdOx1 2309万3399剂。
- 同源疫苗接种程序后风险期贡献2316万8335人年随访。
- 预期发生率由参与站点使用COVID-19疫苗接种前医疗数据按年龄和性别分层获得。
主要发现
- ChAdOx1疫苗首剂后吉兰-巴雷综合征OE比2.49(95%CI 2.15-2.87),脑静脉窦血栓形成OE比3.23(95%CI 2.51-4.09),95%CI下限均大于1.5。
- mRNA-1273疫苗首剂后急性播散性脑脊髓炎OE比3.78(95%CI 1.52-7.78),95%CI下限大于1.5。
- BNT162b2、mRNA-1273和ChAdOx1接种后心肌炎和心包炎OE比显著升高,95%CI下限均大于1.5。
关键数值与推荐
- 优先关注的潜在安全信号定义为OE比95%CI下限(LBCI)大于1.5。
- AESI纳入范围为接种mRNA疫苗(BNT162b2和mRNA-1273)及腺病毒载体疫苗(ChAdOx1)后42天内发生的事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Global COVID Vaccine Safety (GCoVS) Project, established in 2021 under the multinational Global Vaccine Data Network™ (GVDN®), facilitates comprehensive assessment of vaccine safety. This study aimed to evaluate the risk of adverse events of special interest (AESI) following COVID-19 vaccination from 10 sites across eight countries. METHODS: Using a common protocol, this observational cohort study compared observed with expected rates of 13 selected AESI across neurological, haematological, and cardiac outcomes. Expected rates were obtained by participating sites using pre-COVID-19 vaccination healthcare data stratified by age and sex. Observed rates were reported from the same healthcare datasets since COVID-19 vaccination program rollout. AESI occurring up to 42 days following vaccination with mRNA (BNT162b2 and mRNA-1273) and adenovirus-vector (ChAdOx1) vaccines were included in the primary analysis. Risks were assessed using observed versus expected (OE) ratios with 95 % confidence intervals. Prioritised potential safety signals were those with lower bound of the 95 % confidence interval (LBCI) greater than 1.5. RESULTS: Participants included 99,068,901 vaccinated individuals. In total, 183,559,462 doses of BNT162b2, 36,178,442 doses of mRNA-1273, and 23,093,399 doses of ChAdOx1 were administered across participating sites in the study period. Risk periods following homologous vaccination schedules contributed 23,168,335 person-years of follow-up. OE ratios with LBCI > 1.5 were observed for Guillain-Barré syndrome (2.49, 95 % CI: 2.15, 2.87) and cerebral venous sinus thrombosis (3.23, 95 % CI: 2.51, 4.09) following the first dose of ChAdOx1 vaccine. Acute disseminated encephalomyelitis showed an OE ratio of 3.78 (95 % CI: 1.52, 7.78) following the first dose of mRNA-1273 vaccine. The OE ratios for myocarditis and pericarditis following BNT162b2, mRNA-1273, and ChAdOx1 were significantly increased with LBCIs > 1.5. CONCLUSION: This multi-country analysis confirmed pre-established safety signals for myocarditis, pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis. Other potential safety signals that require further investigation were identified.
引用
- Faksova K, Walsh D, Jiang Y, et al. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine. 2024. PMID: 38350768. doi:10.1016/j.vaccine.2024.01.100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。